![]() ![]() ![]() “When the world looked to science to address the pandemic threat of COVID-19, the success of mRNA and other COVID-19 vaccine platforms undoubtedly saved tens of millions of lives. Professor Brendan Crabb AC, Director and CEO of Burnet Institute called the partnership with Moderna’s mRNA Access program a potential ‘game-changer’ for communities needing vaccines to prevent the devastating impact of infectious diseases. Should the results prove promising, Moderna will consider extending the partnership to help progress these candidates through clinical trials. Under the partnership agreement Moderna will provide expertise in designing mRNA vaccines for Burnet’s validated novel candidates in malaria, SARS-CoV-2 and hepatitis C.īurnet’s Vaccine Initiative (BVI) research team will provide vaccine antigens to be modified and optimised by Moderna and returned to the Institute as mRNA candidates ready to test in pre-clinical models. The COVID-19 pandemic has underlined the important role of mRNA vaccines, and innovative scientific thinking is now needed to tackle many of the other high-burden infectious diseases, including malaria which is responsible for the death of half a million people, mostly children, each year. Burnet Institute is to partner with world-leading mRNA vaccine manufacturer Moderna, through their cutting-edge mRNA Access program, to develop novel mRNA vaccines for a range of emerging and neglected infectious diseases aimed at improving the health of communities globally. ![]()
0 Comments
Leave a Reply. |